These experimental results could represent an important complement to the reported effect of anti-PD-1 immunotherapy in inducing antigen-specific cytotoxic T-cell responses against immunogenic epitopes derived from mutant NPM1, which indicates an existing antigen-specific CD8 response in NPMc+ AML patients (Greiner et al., 2020). Here, NPM1 is linked to acute myeloid leukemia.